200 related articles for article (PubMed ID: 24617713)
1. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
Nella AA; Lodish MB; Fox E; Balis FM; Quezado MM; Whitcomb PO; Derdak J; Kebebew E; Widemann BC; Stratakis CA
J Clin Endocrinol Metab; 2014 Sep; 99(9):3055-9. PubMed ID: 24617713
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
[TBL] [Abstract][Full Text] [Related]
3. Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
Pitoia F; Bueno F; Schmidt A; Lucas S; Cross G
Arch Endocrinol Metab; 2015 Aug; 59(4):343-6. PubMed ID: 26331322
[TBL] [Abstract][Full Text] [Related]
4. Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes.
Singer K; Heiniger N; Thomas I; Worden FP; Menon RK; Chen M
J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):993-6. PubMed ID: 24859505
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Baudry C; Paepegaey AC; Groussin L
N Engl J Med; 2013 Aug; 369(6):584-6. PubMed ID: 23924025
[No Abstract] [Full Text] [Related]
6. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
8. Case of multiple endocrine neoplasia 2B with probable ectopic adrenocorticotropic hormone-secreting liver metastasis from medullary thyroid carcinoma.
Kurozumi A; Okada Y; Arao T; Nakamoto Y; Togashi K; Tanaka Y
J UOEH; 2013 Sep; 35(3):193-9. PubMed ID: 24077587
[TBL] [Abstract][Full Text] [Related]
9. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
[TBL] [Abstract][Full Text] [Related]
10. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
15. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib for the treatment of thyroid cancer: an update.
Karras S; Anagnostis P; Krassas GE
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):469-81. PubMed ID: 24502390
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Ton GN; Banaszynski ME; Kolesar JM
Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
[TBL] [Abstract][Full Text] [Related]
20. Remission of Ectopic Cushing Syndrome Secondary to Medullary Thyroid Cancer With Vandetanib and Selpercatinib.
Jazdarehee A; Abdel-Rahman O; Jacquier JE
JCEM Case Rep; 2024 Feb; 2(2):luad174. PubMed ID: 38283729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
